Intelligent Bio Solutions reported a Q3 loss of 44 cents per share with a 20% revenue rise from Q2 and 91% year-over-year ...

This expected patent will enhance INBS’ existing intellectual property ... public offering of 1,500,000 shares of common stock at a public offering price of $2.00 per share of common stock ...

Intelligent Bio Solutions Partners With CenEx ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the ...

Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company delivering rapid, non-invasive testing solutions, reported a 20% sequential r ...

Financial Results for the Fiscal 2025 Third Quarter and Nine-Months Ended March 31, 2025: Total cash and cash equivalents on hand as of March 31, 2025, was $2.81 million. Shareholders equity as of ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc.